Further research is needed to assess GDF-15 and CXCL10 levels in radiotherapy-treated patients and to explore the possibility of using them as a potential biomarker to early detect the risk of cardiovascular diseases in the thoracic radiotherapy-treated patient, thus identifying patients who may benefit from early medical intervention. This evidence concerns the gene CXCL10 and cardiovascular disorder.